Cambiar Investors LLC Sells 81,673 Shares of Haleon plc (NYSE:HLN)

Cambiar Investors LLC decreased its holdings in Haleon plc (NYSE:HLN) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,432,508 shares of the company’s stock after selling 81,673 shares during the period. Cambiar Investors LLC’s holdings in Haleon were worth $13,666,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of HLN. Atomi Financial Group Inc. grew its holdings in shares of Haleon by 48.3% in the third quarter. Atomi Financial Group Inc. now owns 22,518 shares of the company’s stock worth $238,000 after acquiring an additional 7,330 shares during the period. CWM LLC grew its holdings in shares of Haleon by 13.6% in the third quarter. CWM LLC now owns 24,978 shares of the company’s stock worth $264,000 after acquiring an additional 2,996 shares during the period. Ritholtz Wealth Management bought a new stake in shares of Haleon in the third quarter worth $275,000. Procyon Advisors LLC grew its holdings in shares of Haleon by 1.7% in the third quarter. Procyon Advisors LLC now owns 162,911 shares of the company’s stock worth $1,724,000 after acquiring an additional 2,755 shares during the period. Finally, Creative Planning grew its holdings in shares of Haleon by 15.2% in the third quarter. Creative Planning now owns 285,227 shares of the company’s stock worth $3,018,000 after acquiring an additional 37,566 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Price Performance

NYSE HLN opened at $9.70 on Tuesday. The business’s fifty day moving average is $9.53 and its 200 day moving average is $9.79. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a market capitalization of $43.89 billion, a PE ratio of 28.51, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.